Pediatric Hepatic Impairment Dosing in FDA Approvals Between 2002 and 2024.
Saved in:
| Title: | Pediatric Hepatic Impairment Dosing in FDA Approvals Between 2002 and 2024. |
|---|---|
| Authors: | Cassel DA; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA., Burckart GJ; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA., Sahre MD; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA., Abulwerdi GA; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. |
| Source: | Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2026 May; Vol. 119 (5), pp. 1257-1264. Date of Electronic Publication: 2025 Jul 24. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
